During the last session, Organon & Co (NYSE:OGN)’s traded shares were 5.16 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $9.02, reflecting an intraday gain of 2.97% or $0.26. The 52-week high for the OGN share is $23.10, that puts it down -156.1 from that peak though still a striking 10.75% gain since the share price plummeted to a 52-week low of $8.05. The company’s market capitalization is $2.34B, and the average trade volume was 5.20 million shares over the past three months.
Organon & Co (OGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. OGN has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.95.
Organon & Co (NYSE:OGN) trade information
Organon & Co (OGN) registered a 2.97% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.97% in intraday trading to $9.02, hitting a weekly high. The stock’s 5-day price performance is -4.55%, and it has moved by -22.58% in 30 days. Based on these gigs, the overall price performance for the year is -56.38%.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 9.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $10 respectively. As a result, OGN is trading at a discount of -10.86% off the target high and -10.86% off the low.
Organon & Co (OGN) estimates and forecasts
In the rating firms’ projections, revenue will decrease -2.05% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.54B as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 1.55B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.61B and 1.58B respectively. In this case, analysts expect current quarter sales to shrink by -4.40% and then drop by -1.77% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.49%. While earnings are projected to return -5.57% in 2025, the next five years will return -0.14% per annum.
OGN Dividends
Organon & Co is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Organon & Co is 1.12, with the dividend yield indicating at 12.42 percent, continuing the trend of increasing dividends in recent years.
The next largest institutional holding, with 30.21 million shares, is of VANGUARD GROUP INC’s that is approximately 11.7429% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $625.41 million.
Also, the Mutual Funds coming in first place with the largest holdings of Organon & Co (OGN) shares are iShares Trust-iShares Core S&P Small-Cap ETF and Pacer Funds Trust-Pacer US Cash Cows 100 ETF . Data provided on Mar 31, 2025 indicates that iShares Trust-iShares Core S&P Small-Cap ETF owns about 15.93 shares. This amounts to just over 6.13 percent of the company’s overall shares, with a $143.65 million market value. The same data shows that the other fund manager holds slightly less at 11.13, or about 4.28% of the stock, which is worth about $100.39 million.
